• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

AbbVie’s Humira continues to lose market share as biosimilars gain ground

cafead

Administrator
Staff member
  • cafead   Jul 12, 2024 at 11:52: AM
via AbbVie’s Humira (adalimumab) remains the biggest player in the anti-inflammatory space but its market share has dropped to 82% since May 2024, according to Samsung Bioepis’ latest biosimilar report released on Thursday.

article source
 

<